US11485753B2ActiveUtilityA1
Substituted nucleosides, nucleotides and analogs thereof
Est. expiryDec 21, 2032(~6.4 yrs left)· nominal 20-yr term from priority
C07H 19/16A61K 31/7076C07H 19/207C07H 19/213A61P 31/14C07H 19/10C07H 19/20C07H 19/173C07H 19/06A61P 31/20
89
PatentIndex Score
1
Cited by
448
References
20
Claims
Abstract
Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
B 1 is selected from the group consisting of
R 1 is selected from the group consisting of an unsubstituted C 1-6 alkyl and an unsubstituted C 2-6 alkynyl;
each is absent;
R 2 is fluoro;
R P is absent;
R 3 is OH;
R 4 is hydrogen or
R 5A is selected from the group consisting of OH,
R 5B is selected from the group consisting of an OH, —O-unsubstituted phenyl, —O-unsubstituted naphthyl,
R 6B and R 6C are each independently selected from the group consisting of hydrogen and an unsubstituted C 1-6 alkyl;
R 11A , R 12A , R 11B and R 12B are each hydrogen;
R 13 is selected from the group consisting of an unsubstituted C 1-6 alkyl and an unsubstituted C 3-6 cycloalkyl;
R 14 and R 15 are each independently selected from the group consisting of hydrogen and an unsubstituted C 1-6 alkyl;
R 13A and R 13B are each an unsubstituted —O—C 1-4 alkyl;
n is 0 or 1;
R 9 , R 10 and R 11 are each hydrogen; and
Z 1 , Z 1A and Z 1B are each O,
and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
2. The pharmaceutical composition of claim 1 , wherein R 1 is an unsubstituted C 1-6 alkyl.
3. The pharmaceutical composition of claim 1 , wherein R 1 is methyl.
4. The pharmaceutical composition of claim 1 , wherein R 1 is ethynyl.
5. The pharmaceutical composition of claim 1 , wherein R 4 is hydrogen.
6. The pharmaceutical composition of claim 1 , wherein R 4 is
7. The pharmaceutical composition of claim 6 , wherein R 5B is an —O-unsubstituted phenyl; and R 5A is
8. The pharmaceutical composition of claim 6 , wherein R 5A is
9. The pharmaceutical composition of claim 6 , wherein R 5A is
10. The pharmaceutical composition of claim 6 , wherein R 5A is
11. The pharmaceutical composition of claim 10 , wherein R 13A and R 13B are each —O-isopropyl.
12. The pharmaceutical composition of claim 1 , wherein B 1 is
13. The pharmaceutical composition of claim 1 , wherein R 6C is ethyl.
14. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has a structure selected from the group consisting of:
15. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has the structure
16. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has the structure
17. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has a structure selected from the group consisting of:
18. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has a structure selected from the group consisting of:
19. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has a structure selected from the group consisting of:
20. The pharmaceutical composition of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, has the structureCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.